Company intelligence / Profile preview

Haermonics

Ownership: Private
Development stage: Clinical

Overview

Haermonics has developed a novel flush therapy system for continuous cleaning of the pericardial space following cardiac surgery. In randomized clinical trials involving 160 patients, their system demonstrated zero unnecessary reoperations due to prevention of blood/clot accumulation. Additional clinical studies are ongoing or planned to further evaluate safety, usability, and efficacy.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (flush therapy)
Industry: Therapeutic Medical Devices

Partnerships

NLC Health Ventures (investor/venture builder)Academic Medical Center University of Amsterdam (clinical collaborator)ZonMwKansen voor West EFRO grantRabobankBraventure (funding partners)

Beyond the preview

Go deeper on Haermonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haermonics.

Explore the full profile